|
Tiltan Pharma Ltd
Core Business / Technology
Tiltan’s proprietary anti-cancer platform is based on a combination of
agents that target different, non-overlapping aspects of the angiogenic
process. All of these agents are orally bio-available and FDA approved.
The therapy cycle is a carefully timed and balanced in a
patient-friendly treatment regimen that maximizes the synergistic effect
of these agents and combines them into a singularly effective cancer
treatment. The company’s platform technology enables an accelerated
drug-discovery program.
Main Markets / Applications
The treatment of solid tumor cancers is a market of extraordinarily
large size, and multiple modalities of therapeutic options offer good
hope for palliation and cure. Prostate, breast, ovarian, sarcomas and
colon represent existing areas of continued need for novel, effective
approaches.
Uniqueness / Advantage over Existing Products
Patient-friendly — All four drugs, including CTX, are orally
bioavailable. The treatment is administered in liquid form, to be
swallowed once a day.
FDA-approved agents All four agents are FDA approved for use in the
clinic, giving reason to expect a short time to market as well as a good
safety profile.
Safe No major side-effect was observed in more than 40 terminally ill
patients who were treated with Tiltan’s drug-combination for at least 12
weeks. Some of the patients have received treatment for more than a
year.
Effective Objective responses of no progression or partial regression
have been seen in pilot human studies of several solid tumor types.
Broadly applicable Anti-angiogenic therapy is applicable to a broad
spectrum of solid tumors.
Management
Yigal Stav, CEO
Shmuel (Muli) Ben-Sasson, CSO
Hagar Sachs, VP Regulatory affairs
Seeking
Funding sources, strategic partners
Website
www.tiltanpharma.com
|
|
